

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON3SERIAL NO.: 09/225,999
09/1624530

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999GROUP: 1615
1619

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
XQW	AA	3	6	3	4	5	8	4	01/11/72	Poole	424	21	
	AB	3	8	4	5	7	7	0	11/05/74	Theeuwes, et al.	128	260	
	AC	3	8	7	0	7	9	0	03/11/75	Lowey, et al.	424	19	
	AD	3	9	1	6	6	9	9	11/04/75	Theeuwes, et al.	128	145.8	
	AE	4	3	7	7	5	6	8	03/22/83	Chopra	424	31	
	AF	4	3	8	5	0	7	8	05/24/83	Onda, et al.	427	3	
	AG	4	3	8	9	3	9	3	06/21/83	Schor, et al.	424	19	
	AH	4	4	8	3	8	4	7	11/20/84	Augart	424	22	
	AI	4	5	2	0	1	7	2	05/28/85	Lehmann, et al.	525	369	
	AJ	4	5	4	8	9	9	0	10/22/85	Mueller, et al.	525	123	
XQW	AK	4	5	5	7	9	2	9	12/10/85	Lindahl, et al.	424	19	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
XQW	AL	0	2	3	9	9	8	6	09/09/87	EPO (A1)	A61K	9/16	X	
	AM	0	6	6	5	0	1	0	08/02/95	EPO (A1)	A61K	9/26		
	AN	0	2	5	3	1	0	4	01/20/88	EPO (A1)	A61K	9/00	X	
	AO	0	3	8	8	9	5	4	09/26/90	EPO (A2)	A61K	9/14	X	
	AP	0	4	1	5	6	9	3	03/06/91	EPO (A1)	A61K	37/02	X	
XQW	AQ	0	5	3	4	6	2	8	03/31/93	EPO (A1)	A61K	31/485	X	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

XQW	AR	Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain," Clin. Pharmacol. Ther., June 1992, pages 740-746.
	AS	E. Beubler, "Medikamentöse Schmerztherapie: Kriterien, Möglichkeiten, Risiken," Therapiewoche Österreich, 7, 2 (1992), pages 90-96, with English translation.
	AT	Geoffrey K. Gourlay, Ph.D., et al., "Influence of a high-fat meal on the absorption of morphine from oral solutions," Clin. Pharmacol. Ther., October 1989, pages 463-468
XQW	AU	Robert Kaiko, et al., "A Single-Dose Study Of The Effect Of Food Ingestion And Timing Of Dose Administration On The Pharmacokinetic Profile Of 30-MG Sustained-Release Morphine Sulfate Tablets," Current Therapeutic Research, Vol. 47, No. 5, May 1990, pages 869-878.

EXAMINER

XQW

DATE CONSIDERED 9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3

SERIAL NO.: 09/225,959

09/62453

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
XQW	BA	4	7	2	8	5	1	3	03/01/88	Ventouras	424	461	
	BB	4	7	9	7	4	1	9	01/10/89	El-Fakahany	514	356	
	BC	4	8	0	6	3	3	7	02/21/89	Snipes, et al.	71	65	
	BD	4	8	2	8	8	3	6	05/09/89	Elger, et al.	424	419	
	BE	4	8	3	4	9	8	4	05/30/89	Goldie, et al.	424	488	
	BF	5	0	6	8	1	1	9	11/91	Fawzi, et al.	424	461	
	BG	4	8	4	4	9	0	7	07/04/89	Elger, et al.	424	465	
	BH	5	0	1	9	3	9	7	05/91	Wong, et al.	424	473	
	BI	4	9	8	3	7	3	0	01/08/91	Domeshek, et al.	536	69	
	BJ	5	4	5	6	9	2	3	10/10/95	Nakamichi, et al.	424	489	
XQW	BK	5	4	6	0	8	2	6	10/24/95	Merrill, et al.	424	470	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
XQW	BL	0	5	3	5	8	4	1	04/07/93	EPO (A1)	A61K	31/485	X	
	BM	6	5	4	6	6	7	6	06/16/93	EPO (A1)	A61K	31/60	X	
	BN	0	5	4	8	4	4	8	06/30/93	EPO (A1)	A61K	9/50	X	
	BO	0	5	8	0	8	6	0	02/02/94	EPO (A1)	A61K	9/14	X	
XQW	BP	2	1	7	8	3	1	3	02/11/87	Great Britain (A)	A61K	9/14		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

XQW	BQ	Geoffrey K. Gourlay, Ph.D., "The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Symptom Management, Vol. 6., No. 7, October 1991, pages 431-436											
XQW	BR	Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, Vol. 6(4) 1990, pages 17-30											

EXAMINER

XQW Webb

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3SERIAL NO.: 09/225,959
09/162453

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
XQW	CA	5	5	0	8	0	4	2	04/16/96	Oshlack, et al.	424	468	
	CB	5	5	4	9	9	1	2	08/27/96	Oshlack, et al.	424	468	
	CC	5	6	0	1	8	4	2	02/11/97	Bartholomaeus	424	464	
	CD	5	5	2	0	9	3	1	05/28/96	Persson, et al.	424	473	
	CE	5	1	2	2	3	8	4	06/16/92	Paradissis, et al.	424	451	
	CF	4	8	6	1	5	9	8	08/29/89	Oshlack	424	468	
	CG	5	4	1	1	7	4	5	05/02/95	Oshlack, et al.	424	456	
	CH	5	5	0	0	2	2	7	03/19/96	Oshlack, et al.	424	476	
	CI	5	5	8	0	5	7	8	12/03/96	Oshlack, et al.	424	468	
	CJ	5	4	7	2	7	1	2	12/05/95	Oshlack, et al.	424	480	
XQW	CK	5	3	7	8	4	7	4	01/03/95	Morella, et al.	424	469	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
XQW	CL	WO	92	0	1	4	4	6	02/06/92	PCT	A61K	9/50		
	CM	WO	92	0	6	6	7	9	04/30/92	PCT	A61K	9/16	X	
	CN	WO	93	0	4	6	7	5	03/18/93	PCT	A61K	31/16	X	
	CO	WO	93	1	8	7	5	3	09/30/93	PCT	A61K	9/16	X	
XQW	CP	0	1	6	6	6	0	8	8/95	Japan				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

XQW	CQ	N. Yokokawa, et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J, (1991) 67 (Suppl. 2) pages 550-554											
	CR	Physicians Desk Reference 1994, 48 th Edition, pages 1821-1824.											
XQW	CS	D.L. Munday, "Changes in Drug Release Rate 2, Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5 th Cong. Int. Tech. Pharm., 1989, Vol. 2, pp. 55-60.											

EXAMINER

XQW/16

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3

SERIAL NO.: 09/225,850

09/624530

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
XQW	DA	4	9	7	0	0	7	5	11/13/90	Oshlack	424	451	
	DB	5	6	5	6	2	9	5	08/97	Oshlack, et al.	424	468	
	DC	5	9	7	0	1	7	2	09/97	Buxton, et al.	424	495	
	DD	5	6	7	2	3	6	0	09/97	Sackler, et al.	424	490	
	DE	5	5	9	3	6	9	5	01/97	Merrill, et al.	424	480	
	DF	5	6	6	7	8	0	5	09/97	Merrill, et al.	424	473	
	DG	4	9	9	0	3	4	1	02/91	Goldie, et al.	424	484	
	DH	5	2	7	3	7	6	0	12/93	Oshlack, et al.	424	480	
	DI	4	8	6	1	5	9	8	08/89	Oshlack	424	468	
	DJ	4	8	4	4	9	0	9	08/89	Goldie	424	480	
XQW	DK	5	2	6	6	3	3	1	11/93	Oshlack, et al.	424	468	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
XQW	DL	2	1	7	0	1	0	4	7/88	United Kingdom	A61K	9/58		
	DM	WO	94	2	2	4	3	1	10/13/94	PCT	A61K	9/20		
	DN	WO	96	0	0	0	6	6	01/04/96	PCT	A61K	31/485		
	DO	WO	96	0	1	6	2	9	01/25/96	PCT	A61K	31/485		
XQW	DP	WO	94	0	5	2	6	2	03/17/94	PCT	A61K	9/16		

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)

XQW	DQ	A Protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol® to MsContin® in the Management of Patients with Moderate to Severe Cancer Pain" ("the Protocol"). The date of the Protocol is indicated as February 10, 1992 and it bears COD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company.
	DR	Certain Patient Diary Cards, Drug Disposition Records, Case Reports Forms and a listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient.
XQW	DS	Patient consent forms, apparently for four study participants.

EXAMINER

X Q W

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3SERIAL NO.: 09/225,959
09/624530

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
XQW	EA	4	8	3	4	9	8	5		05/89	Elger, et al.	424	488	
	EB	5	0	7	1	6	4	6		12/91	Malkowska	424	497	
	EC	5	2	0	2	1	2	8		04/93	Morella, et al.	424	469	
	ED	5	1	7	8	8	6	8		01/93	Malmqvist, et al.	424	490	
	EE	5	1	3	3	9	7	4		07/92	Paradissis, et al.	424	480	
	EF	4	6	0	0	6	4	5		07/15/86	Ghebre-Sellassie, et al.	428	403	
	EG	4	7	0	8	8	7	4		11/24/87	De Haan, et al.	424	490	
	EH	5	0	2	4	8	4	2		06/18/91	Edgren, et al.	424	473	
	EI	5	1	6	9	6	4	5		12/08/92	Shukla, et al.	424	499	
	EJ	5	2	8	3	0	6	5		02/01/94	Doyon, et al.	424	467	
XQW	EK	5	3	2	1	0	1	2		06/14/94	Mayer, et al.	514	25	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
XQW	EL	WO	96	1	4	0	5	8		03/27/96	PCT	A61K	9/14		
	EM	0	5	3	2	3	4	8		03/17/93	EPO (A2)	A61K	31/135		
	EN	9	0	3	8	3	7	0		06/09/94	EPO (A1)	A61K	31/35		
	EO	9	0	4	7	7	3	2		07/12/90	Australia				
	EP	9	3	4	1	6	5	4		02/16/95	Australia				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	EQ	Certain documents regarding Institutional Review Board Approval for the Faulding-sponsored study.
XQW	ER	Investigator Agreements between the study organizers and certain of the principal investigators.

EXAMINER

XQW/llh

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3

SERIAL NO.: 00/225,959

09/62450

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JKW	FA	4	6	0	9	5	4	2	09/86	Panoz, et al.	424	498	
	FB	5	2	0	6	0	3	0	04/93	Wheatley, et al.	424	490	
	FC	5	2	1	9	5	7	5	06/93	Bommel, et al.	424	490	
	FD	5	2	4	8	5	1	6	09/93	Wheatley, et al.	427	214	
	FE	5	2	5	8	4	3	6	11/93	Wheatley, et al.	524	388	
	FF	5	3	8	4	1	3	0	01/95	Kamada	424	461	
	FG	5	6	3	7	3	2	0	06/97	Bourke, et al.	424	484	
	FH	5	2	8	6	4	9	3	02/94	Oshlack, et al.			
	FI	5	0	0	7	7	9	0	04/91	Shell	424	451	
	FJ	5	3	3	6	7	6	6	07/94	Morella, et al.	424	490	
	FK	5	6	8	1	5	8	5	10/97	Oshlack, et al.	424	494	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	FL	0	2	7	1	1	9	3	06/88	EPO	A61K	31/185	X	
	FM	0	0	9	7	5	2	3	01/84	EPO	A61K	9/26	X	
	FN	WO	93	1	0	7	6	5	06/93	PCT	A61K	9/22	X	
	FO	0	3	7	7	5	1	8	07/90	EPO (A2)	A61K	9/52		
	FP	WO	94	0	3	1	6	1	02/94	PCT	A61L	9/25		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	FQ	Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987											
	FR	J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Journ. Of Pain and Sympton Manag., v 4 (3), pp. 146-151, 1989											
JKW	FS	J. Lapin et al., "Guidelines for use of Controlled Release Oral Morphine in Cancer pln Management," Cancer Nursing, v 12 (4), pp. 202-8, 1989											

EXAMINER

JKW

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3

SERIAL NO.: 09/225,959

09/62453

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						
	GC						
	GD						
	GE						
	GF						
	GG						
	GH						
	GI						
	GJ						
	GK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
XQW	GL	WO 94 0 3 1 6 0	02/94	PCT	A61K	9/32		X
	GM	0 3 7 7 5 1 8	02/07/96	EPO (B1)				
	GN	0 3 2 7 2 9 5	01/89	EPO				X
	GO	6 3 6 3 7 0	06/09/94	EPO (A1)	A61K	31/35		
	GP	2 0 8 2 5 7 3	11/92	Canada				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GQ	R.F. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989)
	GR	H.F. Slowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anaesthesia, 1985, Vol. 40, pp. 438-40.
XQW	GS	MS Contin - Frequency of Daily Dosing, January - November 1990

EXAMINER

Lan B. Kelle

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3SERIAL NO.: ~~09/225,959~~
09/1624530

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
	HB						
	HC						
	HD						
	HE						
	HF						
	HG						
	HH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
XQW	HI	2 1 3 1 3 5 0	01/94	Canada (A1)	A61K	031/135		
	HJ	0 1 0 8 2 1 8	05/16/84	EPO (A2)	A61K	9/22		
	HK	0 1 4 7 7 8 0	07/10/85	EPO (A2)	A61K	9/32		
	HL							
	HM							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	HN	R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Kapanol® Capsules Given Every 24 hours and Every 12 hours with MS Contin® Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain"
	HO	R. West et al., World Congress on Pain Abstracts 997-1001, August 26, 1993.
	HP	Advertisement: Rosanol SR., 1988 Roxane Labs, Inc.
	HQ	R. Kaiko and T. Hunt, Clp. Thera. Vol. 13, No. 4, pages 484-488, 1991
	HR	S. Bloomfield, et al. Clin. Pharmacol. Ther. Vol. 53, No. 4, pages 469-478, 1993
XQW	HS	Advertisement: MS Contin 1986, 1987 The Purdue Frederick Company

EXAMINER XQW

DATE CONSIDERED 9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3SERIAL NO.: 09/225,959
09/624520

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
2QW	IA	4	9	3	5	2	4	6	06/90	Ahrens	424	490	
	IB	2	7	3	8	3	0	3	03/13/56	Blythe	167	82	
	IC	5	0	2	6	5	6	0	06/25/91	Makino, et al.	424	494	
	ID	5	1	3	2	1	4	2	07/21/92	Jones, et al.	247	196	
	IE	3	9	1	6	8	8	9	11/04/75	Russell	128	145.8	
	IF	4	0	8	8	8	6	4	05/09/78	Theeuwes, et al.	219	1211M	
	IG	4	0	6	3	0	6	4	12/13/77	Saunders, et al.	219	121	
	IH	4	1	3	2	7	5	3	01/02/79	Blichare, et al.	264	75	
	II	4	4	2	1	7	3	6	12/20/93	Walters	424	19	
	IJ	4	8	9	4	2	3	4	01/16/90	Sharma, et al.	424	440	
	IK	5	0	2	3	0	8	9	06/11/91	Sakamoto, et al.	424	490	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	IL	WO	93	0	7	8	6	1	04/29/93	PCT	A61K	50		
	IM	WO	92	0	2	2	0	9	02/20/92	PCT (A1)	A61K	9/22	(Abstract)	
	IN	WO	93	0	7	8	5	9	04/29/93	PCT (A1)	A61K	9/16		
	IO	0	2	6	7	7	0	2	05/28/88	EPO (A3)	A61K	914		
	IP	0	3	6	1	6	8	0	07/13/94	EPO (B1)	A61K	9/46		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	IQ	Sustained Release Medications, Noyes Data Corp., pages 3,4, 10-15, 96-99, 335-337 (1980).											
2QW	IR	Flanders, P., et al., "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, vol. 13, No. 6, pp. 1001-1022 (1987)											

EXAMINER

Laura R. Welch

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3SERIAL NO.: ~~09/225,959~~

09/162453

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>QW</i>	JA	5	0	3	0	4	0	0	07/09/91	Danielsen, et al.	264	101	
	JB	5	1	2	6	1	4	5	06/30/92	Evenstad, et al.	424	465	
	JC	5	1	9	6	2	0	3	03/23/93	Boehm	424	469	
	JD	5	2	9	2	4	6	1	03/08/94	Juch, et al.	264	37	
	JE	5	1	6	7	0	0	4	12/01/92	Muhammed, et al.	424	482	
	JF	4	4	4	3	4	2	8	04/17/84	Oshlack	424	22	
	JG	5	6	1	4	2	1	8	03/25/97	Olsson	424	456	
	JH	5	6	2	9	0	1	1	05/13/97	Illum	242	434	
	JI	4	4	6	7	3	7	8	08/84	Hussain	424	260	
	JJ	5	5	0	2	0	5	8	03/96	Mayer, et al.	514	289	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	JK	0	3	6	1	9	1	0	04/04/90	EPO (A1)	A61K	9/16		
	JL	0	3	7	7	5	1	7	04/11/90	EPO (A2)	A61K	31/52		
	JM	0	4	3	0	2	8	7	10/12/94	EPO (B1)	A61K	9/54		
	JN	0	4	5	2	1	4	5	10/16/91	EPO (A2)	A61K	9/14		
	JO	0	5	5	3	3	9	2	08/04/93	EPO (A1)	A61K	9/50		
	JP	0	5	3	3	2	9	7	03/24/93	EPO (A1)	A61K	9/16		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	JQ	McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," <u>International Journal of Pharmaceutics</u> , Vol. 19, pp. 139-148 (1984)											
	JR	Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," <u>Drug Development and Industrial Pharmacy</u> , Vol. 16, No. 8, pp. 1249-1277 (1990)											
	JS	Thomsen, L., Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," <u>Drug Development and Industrial Pharmacy</u> , Vol. 19, No. 15, pp. 1867-1887 (1993)											
<i>QW</i>	JT	Thomsen, L., Juul, et al., "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders," <u>Drug Development and Industrial Pharmacy</u> , Vol. 20, No. 77, pp. 1179-1197 (1994)											

EXAMINER

QW

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3

SERIAL NO.: 09/225,959

09/1624536

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						
	KB						
	KC						
	KD						
	KE						
	KF						
	KG						
	KH						
	KI						
	KJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
20W	KK	0 6 0 9 9 6 1	08/10/94	EPO (A1)	A61K	31/485		
	KL	0 6 3 6 3 7 0	01/01/95	EPO (A1)	A61K	31/485		
	KM	2 0 5 3 6 8 1	01/11/81	Great Britain (B)	A61K	9/22		
	KN	WO 92 0 8 4 5 9	5/29/92	PCT	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	KO	Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," <u>Pelletization</u> , (material elaborated by assistant prof. Lars Juul Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy for the DIE course "Pelletization Technology," November 1992, 106 pages plus 3 appendices
	KP	Thomsen, L. Juul, "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. Part IV: Drug Particles Size, and Binder Composition," <u>Pharmaceutical Technology Europa</u> , pp. 19-24 (October 1994)
	KQ	Maccarrone C. et al.; Single Dose Pharmacokinetics of Kapanol™, a New Oral Sustained-Release Morphine Formulation; <u>Clinical Drug Investigation</u> 1994:7 (5) 262-274
20W	KR	West R. J. Maccarrone C. Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol™ capsules. (Abstract 997) <u>International Association for the Study of Pain, 7th World Congress on Pain</u> , Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)

EXAMINER

R. O. Wells

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3

SERIAL NO. 09/225,959

09/62450

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
	LB						
	LC						
	LD						
	LE						
	LF						
	LG						
	LH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	LI							
	LJ							
	LK							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

XQW	LL	Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol™ (A new sustained release morphine formulation), MST Continus® and morphine solution in cancer patients: pharmacokinetic aspects. (Abstract 998) International Association for the Study of Pain, 7 th World Congress on Pain, Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)
	LM	Cherry DA, Gourley GK, Plummer JL, et al. A comparison of Kapanol™ (a new sustained release morphine formulation), MST Continus® and morphine solution in cancer patients: morphine metabolite profiles and renal function. (Abstract 999) International Association for the Study of Pain, 7 th World Congress on Pain, Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)
	LN	Plummer JL, Cherry DA, Gourlay GK, et al. A comparison of Kapanol™ (a new sustained release morphine formulation) MST Continus® and morphine solution in cancer patients: pharmacodynamic aspects. (Abstract 1000) International Association for the Study of Pain, 7 th World Congress on Pain, Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)
	LO	Toner G, Cramond T, Bishop, et al. Randomized double blind, phase III crossover study of a new sustained-release oral morphine formulation, Kapanol™ capsules, (Abstract 1001) International Association for the Study of Pain, 7 th World Congress on Pain, Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)
XQW	LP	European Journal of Cancer, Once A Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, 29 Oct-2 Nov 1995.

EXAMINER

X Q. Weir

DATE CONSIDERED 9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.93185CON.3SERIAL NO.: ~~09/225,950~~
69/624530

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Mark CHASIN, et al.

FILING DATE:
January 6, 1999

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA						
	MB						
	MC						
	MD						
	ME						
	MF						
	MG						
	MH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	MI							
	MJ							
	MK							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>LQW</i>	ML	European Journal of Cancer; Once A Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, In The Treatment of Cancer Pain: Pharmacokinetic Aspects; Part A General Topics 1995;31 (S5) Suppl: S187 Abs 897 European Conference on Clinical Oncology and Cancer Nursing, Paris, 29 Oct-2 Nov 1995
	MM	European Journal of Cancer; Kadian™/Kapanol™-A Once Daily Morphine Formulation; Part A- General Topics 1995;31 (S5) Suppl: S182 Abs 873 European Conference on Clinical Oncology and Cancer Nursing, Paris, 29 Oct-2 Nov 1995
	MN	Gourlay et al., Proceeding of the 7 th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients: Pharmacokinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management Volume 2 pp 631-643
	MO	Kaiko R.F.; Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient; Anesthesiology and Pain Management 1991 pp 193-212
<i>LQW</i>	MP	MS Contin - Frequency of Daily Dosing (NDTI) - June, 1991 - May, 1992

EXAMINER

L Q Welch

DATE CONSIDERED

9/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.